Department of Toxicology, Pharmacology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno, Czech Republic.
J Control Release. 2011 Apr 30;151(2):193-201. doi: 10.1016/j.jconrel.2011.01.016. Epub 2011 Jan 21.
Hsp90-CA is present in cell wall of Candida pseudohyphae or hyphae-typical pathogenic morphotype for both systemic and mucosal Candida infections. Heat shock protein from Candida albicans (hsp90-CA) is an important target for protective antibodies during disseminated candidiasis of experimental mice and human. His-tagged protein rHsp90 was prepared and used as the antigen for preparation of experimental recombinant liposomal vaccine. Nickel-chelating liposomes (the size around 100nm, PDI≤0.1) were prepared from the mixture of egg phosphatidyl choline and nickel-chelating lipid DOGS-NTA-Ni (molar ratio 95:5%) by hydration of lipid film and extrusion methods. New non-pyrogenic hydrophobised derivative of MDP (C18-O-6-norAbuMDP) was incorporated into liposomes as adjuvans. rHsp90 was attached onto the surface of metallochelating liposomes by metallochelating bond and the structure of these proteoliposomes was studied by dynamic light scattering, AF microscopy, TEM and GPC. The liposomes with surface-exposed C18-O-6-norAbuMDP were well recognised and phagocyted by human dendritic cells in vitro. In vivo the immune response towards this experimental vaccine applied in mice (i.d.) demonstrated both TH1 and TH2 response comparable to FCA, but without any side effects. Metallochelating liposomes with lipophilic derivatives of muramyl dipeptide represent a new biocompatible platform for construction of experimental recombinant vaccines and drug-targeting systems.
Hsp90-CA 存在于假菌丝或菌丝典型的致病性形态,既是全身性和黏膜性念珠菌感染的病原体。来自白色念珠菌的热休克蛋白(hsp90-CA)是实验性播散性念珠菌病中小鼠和人类保护性抗体的重要靶标。His 标记蛋白 rHsp90 被制备并用作制备实验性重组脂质体疫苗的抗原。镍螯合脂质体(大小约为 100nm,PDI≤0.1)由卵磷酯和镍螯合脂质 DOGS-NTA-Ni(摩尔比 95:5%)的混合物通过脂质膜水化和挤出方法制备。新型非致热的 MDP 亲脂衍生物(C18-O-6-norAbuMDP)被掺入脂质体作为佐剂。rHsp90 通过金属螯合键附着在金属螯合脂质体的表面,通过动态光散射、AF 显微镜、TEM 和 GPC 研究这些蛋白脂质体的结构。表面暴露的 C18-O-6-norAbuMDP 的脂质体被体外人树突状细胞很好地识别和吞噬。在体内,应用于小鼠(皮内)的这种实验性疫苗的免疫反应表现出 TH1 和 TH2 反应,与 FCA 相当,但没有任何副作用。具有 muramyl dipeptide 亲脂衍生物的金属螯合脂质体代表了构建实验性重组疫苗和药物靶向系统的新的生物相容性平台。